A Patient-Centered, Combination Intervention to Support Adherence to HIV Pre-exposure Prophylaxis During Pregnancy and Breastfeeding: A Randomized Pilot Study in Malawi

Author:

Chi Benjamin H.1ORCID,Saidi Friday2,Graybill Lauren A.3,Phanga Twambilile2,Mollan Katie R.34,Amico K. Rivet5,Freeborn Kellie1,Rosenberg Nora E.6,Hill Lauren M.6,Hamoonga Twaambo7,Richardson Brian4,Kalua Thokozani8,Phiri Sam9,Mutale Wilbroad10

Affiliation:

1. Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC;

2. UNC Project Malawi, Lilongwe, Malawi;

3. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC;

4. UNC Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC;

5. Department of Health Behavior and Health Education, University of Michigan, Ann Arbor, MI;

6. Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, NC;

7. Department of Population Studies and Global Health, University of Zambia, Lusaka, Zambia;

8. Center for International Health, Education, and Biosecurity, Lilongwe, Malawi;

9. Partners in Hope, Lilongwe, Malawi; and

10. Department of Health Policy and Systems, University of Zambia, Lusaka, Zambia.

Abstract

Background: Daily oral pre-exposure prophylaxis (PrEP) can reduce HIV incidence in pregnant and breastfeeding women, but adherence is essential. Methods: We conducted a pilot randomized trial to evaluate an intervention package to enhance antenatal and postnatal PrEP use in Lilongwe, Malawi. The intervention was based on patient-centered counseling adapted from previous PrEP studies, with the option of a participant-selected adherence supporter. Participants were locally eligible for PrEP and randomized 1:1 to intervention or standard counseling (ie, control) and followed for 6 months. Participants received the intervention package or standard counseling at enrollment, 1, 3, and 6 months. Adherence was measured through plasma and intracellular tenofovir concentrations and scored using a published algorithm. Our primary outcome was retention in care with concentrations consistent with 4–7 doses/week. Results: From June to November 2020, we enrolled 200 pregnant women with the median gestational age of 26 (interquartile range: 19–33) weeks. Study retention was high at 3 months (89.5%) and 6 months (85.5%). By contrast, across the 2 time points, 32.8% of participants retained in the study had adherence scores consistent with 2–5 doses/week while 10.3% had scores consistent with daily dosing. For the composite primary end point, no substantial differences were observed between the intervention and control groups at 3 months (28.3% vs. 29.0%, probability difference: −0.7%, 95% confidence interval: −13.3%, 11.8%) or at 6 months (22.0% vs. 26.3%, probability difference: −4.3%, 95% confidence interval: −16.1%, 7.6%). Conclusions: In this randomized trial of PrEP adherence support, retention was high, but less than one-third of participants had pharmacologically confirmed adherence of ≥4 doses/week. Future research should focus on antenatal and postnatal HIV prevention needs and their alignment across the PrEP continuum, including uptake, persistence, and adherence.

Funder

National Institute of Allergy and Infectious Diseases

National Institute of Mental Health

Fogarty International Center

National Center for Advancing Translational Sciences

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3